Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)
about
PCSK9 and triglyceride-rich lipoprotein metabolismDynamics of hepatic and intestinal cholesterol and bile acid pathways: The impact of the animal model of estrogen deficiency and exercise trainingSortilin, encoded by the cardiovascular risk gene SORT1, and its suggested functions in cardiovascular diseaseLipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptorLDL-Cholesterol: Standards of Treatment 2016: A German Perspective.The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functionsLipid, blood pressure and kidney update 2013.PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers.Low density lipoprotein receptor class A repeats are O-glycosylated in linker regionsThe elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Local effects of human PCSK9 on the atherosclerotic lesion.Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.Atherosclerosis: cell biology and lipoproteinsCommon Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.Site-1 protease-activated formation of lysosomal targeting motifs is independent of the lipogenic transcription controlOn the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.Combined Effects of Rosuvastatin and Exercise on Gene Expression of Key Molecules Involved in Cholesterol Metabolism in Ovariectomized RatsDecreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9.Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.PCSK9 targets important for lipid metabolismUpdate on lipoprotein(a) as a cardiovascular risk factor and mediator.The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.Managing the lipid profile of coronary heart disease patients.The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.PCSK9 at the crossroad of cholesterol metabolism and immune function during infections.The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.Endoplasmic Reticulum Stress and Ca2+ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism.Decreased serum PCSK9 levels after ischaemic stroke predict worse outcomes.Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance.Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol.
P2860
Q26796287-7065B18A-1566-4426-8EA7-414BF78533FBQ28073180-0B9E4577-FA93-4254-AF52-5EB1EAF0ABA6Q28257511-E2F14D87-C4EF-4E45-8675-6ACAAFF53DDFQ28258969-147FABA4-342A-44DF-9E4E-2C81E2B41DA7Q30248925-0914BB51-44D9-4128-851A-3296BBE68270Q30541820-7F5DE97E-E445-4706-890C-43F569774F67Q33574532-7CFA4AA7-F4FF-40D2-A11C-D8AB9E7F9CD5Q33625574-2AD8AF69-ABC6-4772-97A8-0DFAC4551A4BQ33792840-0E77A92B-B8F8-4FC1-8A41-790702884CABQ33804948-5A1CC2F6-B02B-4F41-9DE6-23A948155CD6Q34458693-6790E256-87A1-40F8-9AD9-C14C3EDC4592Q34492178-04DC092D-85F9-4B88-9555-2E2D93752936Q34536594-63AF527C-74E6-4F9A-A84C-C5B3A7480141Q35241610-26D38C4B-CCE1-4E96-9EF3-D9D6BC0DDCCAQ35612555-4B540576-380B-45AB-ABDB-3B614B3B5A81Q35883857-488592E4-3B97-4347-A0F5-4744BE6580B8Q35886328-ED409747-28A0-439E-A8E3-20AC81C83457Q36035643-BEA4FAE8-7E13-4ADE-954C-2CB2DECA6902Q36196833-56B6E616-505C-4DAF-89A6-90394AFFFB21Q36197815-758E7F08-B06A-4DC9-969D-799EAA7528EDQ36281706-8317EBFD-EB9D-4236-8537-570D3ED97916Q36812669-BA749A9A-411C-4984-A855-9932845E3F8DQ36930207-96CD5AE7-2634-47F1-9214-AFADCF814B91Q37115391-2DAC9CDA-A755-437B-B43F-B58E076CE28CQ37116362-28FFAE0D-6E50-42C6-B16F-2EBD748AA8E5Q37636912-1F330310-D6E8-4486-A361-81EED29FDA49Q37703261-CB5B2C84-D16D-4489-BFB7-3E78C8F0F7B6Q38132701-D08E096A-68BF-4C6A-88D2-F3DF24933368Q38151675-6CABCB79-EDA8-4963-8688-2C0532595146Q38855416-3A36EC5D-9548-4183-84AF-EE9BC82E6483Q38934909-C62272CF-2CDB-44C5-AA85-F1B9BA37A213Q39030028-CF05F2B4-F229-4FE3-B104-E4AC644D663FQ39072663-DD805AE5-433D-44E5-B7DC-785F18125D5BQ39080645-7CD4EFF3-C64C-4241-9822-A84319A88A24Q40445739-F336728D-5FC4-4CE0-B024-DCE0C89CA15EQ40530815-B0CF9E15-748E-4BEB-A7EA-FAE1496E1573Q40595854-71688EDE-E43A-40BF-AA39-507B59962417Q41064722-C03E3E35-FC01-4A9B-89CD-557AC13C6FF6Q41153491-797A3779-3ECC-4C10-A9F8-13DA4066B774Q42367561-34A7E6EC-67C9-4615-B145-C9530370CEB0
P2860
Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Proprotein convertase subtilis ...... ptor-related protein 1 (LRP-1)
@ast
Proprotein convertase subtilis ...... ptor-related protein 1 (LRP-1)
@en
type
label
Proprotein convertase subtilis ...... ptor-related protein 1 (LRP-1)
@ast
Proprotein convertase subtilis ...... ptor-related protein 1 (LRP-1)
@en
prefLabel
Proprotein convertase subtilis ...... ptor-related protein 1 (LRP-1)
@ast
Proprotein convertase subtilis ...... ptor-related protein 1 (LRP-1)
@en
P2093
P2860
P1433
P1476
Proprotein convertase subtilis ...... ptor-related protein 1 (LRP-1)
@en
P2093
Eustache Paramithiotis
Marie-Claude Asselin
Maryssa Canuel
Xiaowei Sun
P2860
P304
P356
10.1371/JOURNAL.PONE.0064145
P407
P577
2013-05-13T00:00:00Z